Fig. 3

Apoptosis and SOCS/STAT signaling differentiate responders to methotrexate-based therapy from non-responders. A Network of unique active interactions in conventional synthetic DMARD responders. Cluster R1. Cell survival genes part of the PI3K-Akt signaling pathway (53.1% enrichment). Cluster R2. Extracellular matrix receptor genes (100% enrichment). Cluster R3. Chemokines receptors binding chemokines (100% enrichment). B Robust linear regression of SOCS2 and STAT2 with interaction term associated with response. p-value of the gene to response interacting term is shown. C Logistic regression of response as a function of SOCS2 and STAT2. p-value of the response to gene interacting term is shown. Expression of STAT2 is dichotomized at ± 1 standard deviation. D Receiver operating characteristic curve analysis of the response prediction ability of the robust linear model incorporating the ratio term (black line) or not (dotted blue line)